Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 243111 for:    ALL
Previous Study | Return to List | Next Study

10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by Indonesia University
Information provided by (Responsible Party):
Ari Fahrial Syam, Indonesia University Identifier:
First received: April 25, 2017
Last updated: April 27, 2017
Last verified: April 2017
Helicobacter pylori is a bacterium estimated to colonize in the gastrointestinal tract of the half population in the world. Colonization of this bacteria is suspected to be one of the main risk factor for the occurrence of various abnormalities of the upper gastrointestinal tract, such as peptic ulcer and gastrointestinal cancer. The Experts recommend giving triple therapy regimens as first-line eradication therapy for Helicobacter pylori infection. The recommended duration of triple therapy is 10-14 days. However, recent studies suggest triple therapy with longer duration will provide a higher percentage of eradication. This study wanted to show whether 14 days of triple therapy was better than 10 days in Helicobacter pylori eradication.

Condition Intervention Phase
Helicobacter Pylori Infection
Drug: Rabeprazole Sodium 20mg
Drug: Clarithromycin 500mg
Drug: Amoxicillin 500 Mg
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Masking Description:
Randomized-double blinded Clinical Trials
Primary Purpose: Treatment
Official Title: Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial

Resource links provided by NLM:

Further study details as provided by Indonesia University:

Primary Outcome Measures:
  • Eradication of Helicobacter pylori infection [ Time Frame: 4 weeks after completed therapy ]
    Urea Breath Test after therapy

Estimated Enrollment: 73
Actual Study Start Date: October 3, 2016
Estimated Study Completion Date: May 12, 2017
Estimated Primary Completion Date: May 5, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 14 days triple therapy
Rabeprazole Clarithromycin Amoxicillin
Drug: Rabeprazole Sodium 20mg
Twice daily
Other Name: Pariet
Drug: Clarithromycin 500mg
Twice daily
Other Name: Bicrolid
Drug: Amoxicillin 500 Mg
Twice daily
Other Name: Amoxicillin generic
Placebo Comparator: 10 days triple therapy
Rabeprazole Clarithromycin Amoxicillin
Drug: Rabeprazole Sodium 20mg
Twice daily
Other Name: Pariet
Drug: Clarithromycin 500mg
Twice daily
Other Name: Bicrolid
Drug: Amoxicillin 500 Mg
Twice daily
Other Name: Amoxicillin generic

Detailed Description:

This is a double-blinded randomized clinical trials, to determine the proportion of eradication of Helicobacter pylori infection using a triple therapy regimen for 10 days and 14 days. The triple therapy regimen was a proton pump inhibitor (Rabeprazole 20 mg twice daily), Amoxicillin 1000 mg twice daily, and Clarithromycin 500 mg twice daily.

Patients with dyspepsia and no improvement for at least 2 weeks with empiric therapy (lifestyle education, antacid, H2-antagonist, or proton pump inhibitor), are further investigated to determine the presence of Helicobacter pylori infection using invasive (Esophagoduodenoscopy/EGD) or non-invasive methods (Urea Breath Test/UBT).

Patients with positive results on UBT or histology examination from EGD and fulfill inclusion and exclusion criteria are included as research subjects, then randomly assigned to determine the subject of the study into the sample of study entry in group 1 or group 2.

All subjects will be required to fill out informed consent, demographic data, anthropometric measurements, and questionnaires.

Research subjects will get triple therapy regimen for Helicobacter pylori infection in the form of Proton Pump Inhibitor (Rabeprazole 2 x 20 mg), Amoxicillin 2 x 1000 mg, and Clarithromycin 2 x 500 mg.

Pharmacy will create two sets of regimens, in which one group of regimens contains triple therapy regimens for 10 days followed by the same regimen for 4 days, while another regimen group contains triple therapy regimens for 10 days Day followed by placebo for 4 days. Neither the researcher nor the study subjects knew the triple therapy regimen given to group 1 and group 2 subjects, and only became known after the end of the study.

All subjects will be monitored given drug consumption and evaluated regularity, complaints, and adverse effects arising for 14 days by researchers. The patient is given a control card to write down medication time and any possible complaints or side effects of drug allergic reactions, epigastric pain, headache, discomfort, and nausea / vomiting, and other side effects will be observed during the study. The patient will be determined whether the study will continue or not.

After the therapy was completed, the subjects of the study will be re-examined as an evaluation of eradication success, at least 28 days after completion of triple therapy regimen.

If UBT negative results obtained at the time of evaluation, the eradication is success, when positive UBT results are obtained at the time of evaluation, eradication is failed and the subjects are persistent with first-line therapy.

Persistent patients are encouraged to undergo an EGD at Cipto Mangunkusumo Hospital for the culture of Helicobacter pylori infection resistance. If the patient is not willing to be underwent EGD, then the patient is given second-line treatment regimen of Levofloxacin 2 x 500 mg, Amoxicillin 2 x 1000 mg, and Rabeprazole 2 x 20mg.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years or older patients who are proven to be infected by Helicobacter pylori based on positive in Urea Breath Test or positive in histopathologic examination of biopsy in antrum and corpus of gaster through esophagoduodenoscopy.

Exclusion Criteria:

  • Patients refuse to follow the research
  • Patient has had previous eradication therapy of Helicobacter pylori infection.
  • The patient is pregnant or breastfeeding
  • Patients have a history of allergy to one component of triple therapy regimen (proton pump inhibitor, penicillin, and / or macrolide) before.
  • Patients are known to have impaired liver function, evidenced by ALT values within normal limits, and no previous liver disease.
  • Patients were found to have arrhythmias or obtained QT wave elongation on electrocardiographic
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03134378

Contact: Ari F Syam, Dr. +62818706199
Contact: Ryan Herardi, dr. +6281585089087

Cipto Mangunkusumo Hospital Recruiting
Jakarta Pusat, DKI Jakarta, Indonesia, 10430
Contact: Ari F Syam, Dr.    +62818706199   
Contact: Ryan Herardi, dr.    +6281585089087   
Sponsors and Collaborators
Indonesia University
  More Information

Responsible Party: Ari Fahrial Syam, Dr. dr. SpPD, K-GEH, MMB, FACP, Indonesia University Identifier: NCT03134378     History of Changes
Other Study ID Numbers: 16-10-311
Study First Received: April 25, 2017
Last Updated: April 27, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Indonesia University:
Helicobacter pylori
triple therapy

Additional relevant MeSH terms:
Communicable Diseases
Helicobacter Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors processed this record on April 28, 2017